In the last ten years, enormous efforts directed toward the discovery of specific Shp2 inhibitors as potential therapeutic agents for hematologic malignancies and solid tumors have been continuing in several research groups6, 7, 8, 9, 10, 11. Here, PTPN11 is linked to hematologic disorder.